Accolade Pharmaceuticals Appoints James P. Kemp, MD. Chief Medical Officer
April 30, 2014
WILMINGTON, Del.—Accolade Pharmaceuticals is proud to announce today the appointment of Dr. James P. Kemp, as Chief Medical Officer. He will be the newest member of the Accolade management team, which includes six members with extensive backgrounds in the biopharmaceutical field. Dr. Kemp’s research and experience with allergic diseases will be key in furthering the development of Accolade’s current and future product endeavors in treating allergic disorders.
As a clinical professor in the Division of Immunology and Allergy at the University of California in San Diego, Dr. Kemp has both led and participated in extensive immunological research including research on the use of the leukotriene receptor antagonists (LRTAs). “We are pleased to have Jim join us and confident that his clinical experience will serve Accolade well in our effort to expand development of our topical program for zafirlukast,” says Accolade’s Co-Founder and Chairman, Mitchell Glass, MD.
After earning his medical degree at the University of Virginia in Charlottesville, Va., Dr. Kemp completed his internship in pediatrics at the University of Florida in Gainesville, Fla., followed by a residency at Emory University, Grady Memorial Hospital, in Atlanta. He also completed both his fellowship and residency in Pediatric Allergy and Immunology at the University of California at San Francisco. Dr. Kemp is currently a practicing allergist and immunologist in San Diego.
About Accolade Pharmaceuticals LLC
Accolade is a private, specialty biopharmaceutical company that focuses on the development of known drug products for the treatment of allergic diseases. Founded in 2012, Accolade is quickly advancing a pipeline of products for treating multitude allergic conditions, including allergic rhinitis, conjunctivitis and skin disorders. For more information about Accolade Pharmaceuticals LLC, please visit: www.accoladepharma.com.